Last updated on November 2017

A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)


Brief description of study

A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)

Detailed Study Description

The purpose of this study is to evaluate the efficacy and safety of NX-1207 and to see if it could be useful for men with BPH. The study treatment will consist of either an injection of NX-1207 or of a placebo into the prostate. If you end up receiving the placebo, you will be offered the chance to receive NX-1207 at the end of the study. The study will last for 12 months.

Inclusions:

  • Male ≥ 45 years of age
  • History of BPH for at least 1 year

Exclusions:

  • Acute or chronic Prostatitis in the past 12 months
  • Urinary Tract Infections more than once in the past 12 months
  • Previous surgical or invasive prostate treatments such as TURP, TUMT, and TUNA, laser or any minimally invasive treatments.
  • History of urinary retention in the past 12 months
  • Prostate or bladder cancer
  • PSA ≥ 10 ng.ml

Clinical Study Identifier: TX1457

Contact Investigators or Research Sites near you

Start Over

Debbie Johnson, CCRC

First Urology, PSC
Jeffersonville, IN USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.